Is the mechanism of COVID-19 coagulopathy still a rabbit's hole?

Rajan, Ashna; Thirunavukkarasu, Ganesh Keshav; Lockey, Richard F; Kolliputi, Narasaiah

Rajan, Ashna; Thirunavukkarasu, Ganesh Keshav; Lockey, Richard F; Kolliputi, Narasaiah.

Afiliação

Rajan A; Division of Geriatrics Medicine, Brown University Alpert School of Medicine, Providence, RI, 02903, USA.
Thirunavukkarasu GK; Division of Cardiovascular Medicine, Department of Internal Medicine, State University of New York-Downstate Medical Center, Brooklyn, NY, 11203, USA.
Lockey RF; Division of Allergy and Immunology, Department of Internal Medicine, Morsani College of Medicine, University of South Florida, 2901 Bruce B. Downs Blvd, Tampa, FL, 33612, USA.
Kolliputi N; Division of Allergy and Immunology, Department of Internal Medicine, Morsani College of Medicine, University of South Florida, 2901 Bruce B. Downs Blvd, Tampa, FL, 33612, USA. nkollipu@usf.edu.

J Cell Commun Signal ; 16(1): 1-3, 2022 Mar.

Article em En | MEDLINE | ID: mdl-34076828

ABSTRACT

ABSTRACT

The pathophysiology of COVID-19 is an enigma with its severity often determined by the extent of coagulopathy. Several regulatory pathways targeted by the SARS-CoV-2 include the renin-angiotensin system, von Willebrand Factor, and most importantly, the complement pathway. This article discusses these pathways to help design potential future therapies.

Palavras-chave

ACE2; COVID-19; Coagulopathy; Complement; SARS-CoV2; Thromboinflammation

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: J Cell Commun Signal Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google